Edesa Biotech, Inc.

NASDAQ:EDSA

Biotechnology

Healthcare
$5.75 +1.31%

+$0.09 today

Market cap
$55.39M
Beta
1.07
P/E (TTM)
-5.5
EPS (TTM)
-$1.27
52W Low $0.72High $20.32

Volume 0.07M

Average 0.62M

EDSA Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Edesa Biotech, Inc.NASDAQ: EDSA

Accumulated OCI · Q2 FY2026 · quarter ended Mar 2026

Accumulated OCI remains negative

Q2 FY2026 Accumulated OCI was -$186.09K, compared with -$287.69K a year earlier.

Context

  • Accumulated OCI amounted to 1.5% of total assets at the end of Q2 FY2026, down 0.2 pp from a year earlier.
  • Accumulated OCI grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +35.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$186.09K-8.8% QoQ
Last fiscal yearSep 2025
-$165.77K+31.7% YoY
Year agoMar 2025
-$287.69K+35.3% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.3%——
1 year+31.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
(165.77K) USD
Year-over-year change
+31.7%

Accumulated OCI vs competitors

How EDSA compares with its peers on the latest reported figures

  • EDSA's Mar 2026 Accumulated OCI of -$186.09K is the highest of the 2 companies compared; the peer median is -$1.72M.
  • Its year-over-year change of +35.3% is the lowest of 2, against a peer median of +54.7%.
  • Accumulated OCI amounts to 1.5% of total assets for EDSA, versus a peer median of 1.8%.
EDSA Competitors Peer median
Accumulated OCI for EDSA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EDSAEdesa Biotech, Inc.Mar 2026-$186.09K +35.3%—1.5%
DWTXDogwood Therapeutics, Inc.Mar 2026-$1.72M +54.7%—1.8%
Peer median (excluding EDSA) -$1.72M+54.7%—1.8%

Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Cash & Equivalents7.84M7.09M5.36M1.04M10.79M
Short-term Investments00000
Net Receivables3.3M1.26M626.54K270.91K642.87K
Inventory00000
Other Current Assets948.65K745.54K448.91K367.39K77.84K
Total Current Assets12.09M9.09M6.44M1.68M11.51M
Property, Plant & Equipment (Net)111.56K31.16K100.08K18.36K0
Goodwill00000
Intangible Assets2.38M2.28M2.18M2.08M1.98M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0171.46K173.49K41.15K39.97K
Total Non-current Assets2.49M2.48M2.45M2.14M2.02M
Total Assets14.58M11.58M8.89M3.81M13.53M
Account Payables1.38M2.12M1.75M1.81M0
Short-term Debt00000
Tax Payables00000
Deferred Revenue0(2.12M)000
Other Current Liabilities02.12M001.08M
Total Current Liabilities1.46M2.14M1.82M1.83M1.08M
Long-term Debt00000
Deferred Tax Liabilities000126K0
Deferred Revenue (Non-current)00000
Other Non-current Liabilities47.2K43.66K000
Total Non-current Liabilities67.71K43.66K19.77K126K0
Total Liabilities1.53M2.18M1.84M1.83M1.08M
Common Stock34.89M42.47M46.64M47.24M54.52M
Retained Earnings(26.5M)(44.04M)(52.42M)(58.59M)(65.91M)
Accumulated OCI(205.26K)(213.6K)(214.65K)(242.61K)(165.77K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity13.06M9.39M7.05M1.98M12.45M
Total Debt99.32K18.98K94.49K19.87K0
Net Debt(7.74M)(7.07M)(5.27M)(1.02M)(10.79M)

Edesa Biotech, Inc.

NASDAQ:EDSA

Intrinsic Alpha fair value

Locked

Current Price

$5.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.